{"filing":{"accession_number":"0001213900-26-102358","cik":"0001985062","ticker":"PBMWW","company_name":"PSYENCE BIOMEDICAL LTD.","form":"6-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"ea0306308-6k_psyence.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1985062/000121390026102358/ea0306308-6k_psyence.htm"},"events":[{"id":34463,"run_id":31709,"accession_number":"0001213900-26-102358","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"The press release discloses a material strategic investment and share exchange between Psyence BioMed and PsyLabs: a cash investment of up to US$5 million (with US$2.4 million committed) and a reciprocal share-for-share exchange valued at approximately US$9 million on each side. These transactions materially alter ownership stakes (PsyLabs' ownership in Psyence BioMed increases from ~30.22% to ~49.89%, and Psyence BioMed's ownership in PsyLabs increases from ~29.17% to ~41.13%), constitute related-party transactions, and are subject to customary closing conditions and regulatory approvals. This represents a material acquisition/investment activity affecting control and capital structure.","company_name":"PSYENCE BIOMEDICAL LTD.","ticker":"PBMWW","filing_date":"2026-09-23","form":"6-K","submitted_at":null,"items":[{"id":38190,"accession_number":"0001213900-26-102358","item_number":"EX-99.1","item_title":"ea030630801ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The press release discloses a material strategic investment and share exchange between Psyence BioMed and PsyLabs: a cash investment of up to US$5 million (with US$2.4 million committed) and a reciprocal share-for-share exchange valued at approximately US$9 million on each side. These transactions materially alter ownership stakes (PsyLabs' ownership in Psyence BioMed increases from ~30.22% to ~49.89%, and Psyence BioMed's ownership in PsyLabs increases from ~29.17% to ~41.13%), constitute related-party transactions, and are subject to customary closing conditions and regulatory approvals. This represents a material acquisition/investment activity affecting control and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T11:02:45.090616+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38190,"accession_number":"0001213900-26-102358","item_number":"EX-99.1","item_title":"ea030630801ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The press release discloses a material strategic investment and share exchange between Psyence BioMed and PsyLabs: a cash investment of up to US$5 million (with US$2.4 million committed) and a reciprocal share-for-share exchange valued at approximately US$9 million on each side. These transactions materially alter ownership stakes (PsyLabs' ownership in Psyence BioMed increases from ~30.22% to ~49.89%, and Psyence BioMed's ownership in PsyLabs increases from ~29.17% to ~41.13%), constitute related-party transactions, and are subject to customary closing conditions and regulatory approvals. This represents a material acquisition/investment activity affecting control and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T11:02:45.090616+00:00","company_name":"PSYENCE BIOMEDICAL LTD.","ticker":"PBMWW","filing_date":"2026-09-23"}]}